NEW YORK: Zambon S.p.A., an international pharmaceutical company committed to the Central Nervous System (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, has announced that the European Commission has approved the use of Xadago® (safinamide) for the treatment of idiopathic Parkinson’s disease (PD).
Xadago® has been approved for mid-to late-stage fluctuating patients as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products. The decision follows the Positive Opinion adopted by the Committee for Medicinal Products for Human Use on December 18th, 2014 and is applicable to all 28 European Union member countries, as well as Iceland, Liechtenstein and Norway…